# A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Source: https://onco.cc/trials/nct05957367/  
OnCo record `nct05957367` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ripretinib in advanced solid tumours, run by Deciphera Pharmaceuticals, LLC, now recruiting.

## Summary

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies is a phase 1/2 interventional study registered as NCT05957367 by Deciphera Pharmaceuticals, LLC, with 94 participants planned, started 2023-09-28 and due to reach its primary completion in 2027-03. Interventions recorded: Inlexisertib and Ripretinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05957367
- Phase: 1/2
- Setting: A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- Sponsor: Deciphera Pharmaceuticals, LLC
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT05957367: https://clinicaltrials.gov/study/NCT05957367

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Inlexisertib](https://onco.cc/drugs/inlexisertib/), [Ripretinib](https://onco.cc/drugs/ripretinib/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct05957367.json